
SIL
NSEPrice History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Trend
Price above all key MAs — strong uptrend
Price Action
Support & Resistance Levels
Volume Analysis
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Sep '25 |
|---|---|---|---|---|
| Revenue | ₹7.7 Cr | ₹8.6 Cr | ₹10.5 Cr | ₹6.4 Cr |
| Net Profit | ₹-5.6 Cr | ₹-4.5 Cr | ₹-1 Cr | ₹-6.7 Cr |
| EPS | ₹-0.87 | — | ₹-0.16 | ₹-1.03 |
| Operating Profit | ₹-4.5 Cr | ₹-3.3 Cr | ₹31,19,000 | ₹-5.2 Cr |
Peer Comparison
Real Estate related servicesPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| P. E. Analytics Limited | ₹235.00 | +2.62% | 15.3 | ₹246 Cr small Cap | |
| Rudrabhishek Enterprises Limited | ₹64.00 | -2.25% | — | ₹116 Cr small Cap | |
| Standard Industries Limited | ₹16.46 | +2.55% | — | ₹106 Cr small Cap | |
| Landmark Property Development Company Limited | ₹6.41 | +0.47% | 57.3 | ₹86 Cr small Cap | |
| Homesfy Realty Limited | ₹112.00 | +0.00% | — | ₹36 Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 20 Feb 2026 | Interim Dividend - Re 0.55 Per Share | INTERIM_DIVIDEND |
| 30 Jul 2024 | Dividend - Rs 0.55 Per Share | DIVIDEND |
| 28 Mar 2024 | Interim Dividend - Rs 0.50 Per Share | INTERIM_DIVIDEND |
| 25 Jul 2023 | Dividend - Re 0.25 Per Share | DIVIDEND |
| 01 Jun 2023 | Interim Dividend - Re 0.80 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for SIL
View AllMedicines with over 12% alcohol can no longer be sold without prescription: Govt
In a new regulatory change, medications with alcohol content exceeding twelve percent will require a prescription from a doctor. This decision treats these products like standard prescription drugs, compelling manufacturers to obtain the necessary licenses. Furthermore, pharmacies are now tasked with rigorous record-keeping to mitigate potential abuse and ensure that genuine medical use is preserved under enhanced scrutiny.

Stock Alert: TCS, M&M, Anand Rathi Wealth, Havells India - Business Standard
Stock Alert: TCS, M&M, Anand Rathi Wealth, Havells IndiaBusiness Standard
Shriram Finance taps foreign banks for cheaper debt
DBS Bank, HSBC, Standard Chartered and MUFG are among the banks which have lined up to provide this loan. ET could not ascertain the names of all lenders. "The loan has been launched with half a dozen banks already lining up for the first underwriting.